Fasenra proven safe for Long-Term asthma control in Real-World study
NCT ID NCT03588546
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at the long-term safety and effectiveness of Fasenra (benralizumab) in 653 people with severe asthma that wasn't controlled by other treatments. Researchers tracked side effects and asthma control over time. The goal was to confirm that Fasenra works well and is safe for long-term use in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fasenra (benralizumab)
What this could lead to
If successful, this study confirms that Fasenra is safe and effective for long-term asthma control, helping patients manage their condition better.
What could go wrong
This is a post-marketing observational study, not a new treatment test. It may not show major new benefits, and individual results can vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Aichi, D3250C00057, Japan
-
Research Site
Akita, D3250C00057, Japan
-
Research Site
Aomori, D3250C00057, Japan
-
Research Site
Chiba, D3250C00057, Japan
-
Research Site
Ehime, D3250C00057, Japan
-
Research Site
Fukuoka, D3250C00057, Japan
-
Research Site
Gunma, D3250C00057, Japan
-
Research Site
Hiroshima, D3250C00057, Japan
-
Research Site
Hokkaido, D3250C00057, Japan
-
Research Site
Hyōgo, D3250C00057, Japan
-
Research Site
Ibaraki, D3250C00057, Japan
-
Research Site
Kagawa, D3250C00057, Japan
-
Research Site
Kagoshima, D3250C00057, Japan
-
Research Site
Kanagawa, D3250C00057, Japan
-
Research Site
Kumamoto, D3250C00057, Japan
-
Research Site
Kyoto, D3250C00057, Japan
-
Research Site
Mie, D3250C00057, Japan
-
Research Site
Miyagi, D3250C00057, Japan
-
Research Site
Numakunai, D3250C00057, Japan
-
Research Site
Okayama, D3250C00057, Japan
-
Research Site
Okinawa, D3250C00057, Japan
-
Research Site
Osaka, D3250C00057, Japan
-
Research Site
Ōita, D3250C00057, Japan
-
Research Site
Saitama, D3250C00057, Japan
-
Research Site
Shiga, D3250C00057, Japan
-
Research Site
Tochigi, D3250C00057, Japan
-
Research Site
Tokyo, D3250C00057, Japan
-
Research Site
Yamagata, D3250C00057, Japan
-
Research Site
Yamaguchi, D3250C00057, Japan